10-Q FAIR VALUE MEASUREMENTS - Schedule of Liabilities Measured on Recurring Basis (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 04, 2020
Sep. 08, 2020
Assets:          
Investments in equity securities $ 1,107,742 $ 925,819 $ 3,979,723    
Liabilities:          
LINICO acquisition derivative liability   (2,743,162)      
Tonogold Resources, Inc.          
Assets:          
Investments in equity securities         $ 7,607,263
Tonogold note receivable   7,255,000 5,498,500   $ 6,141,497
Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities 1,100,293 910,558 3,939,558    
M C U          
Assets:          
Tonogold note receivable       $ 755,866  
Fair Value, Measurements, Recurring          
Assets:          
Total assets measured at fair value 1,107,742 8,522,818 9,743,350    
Total assets measured at fair value   8,522,819      
Liabilities:          
GenMat derivative (4,990,000) (6,130,000)      
Total Liabilities (6,403,162) (8,873,162)      
Total Liabilities   (8,873,162)      
Fair Value, Measurements, Recurring | Tonogold Resources, Inc.          
Assets:          
Tonogold note receivable   7,255,000 5,498,500    
Fair Value, Measurements, Recurring | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities 1,100,293 910,558 3,939,558    
Fair Value, Measurements, Recurring | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities   910,559      
Fair Value, Measurements, Recurring | M C U          
Assets:          
Derivative asset   342,000 265,127    
Fair Value, Measurements, Recurring | Elevation          
Assets:          
Investments in equity securities 7,449 15,260 40,165    
Fair Value, Measurements, Recurring | LINICO Corporation          
Liabilities:          
LINICO acquisition derivative liability   (2,743,162)      
LINICO acquisition derivative liability (1,413,162) (2,743,162)      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1)          
Assets:          
Total assets measured at fair value 1,107,742 925,818 3,939,558    
Total assets measured at fair value   925,819      
Liabilities:          
GenMat derivative 0 0      
Total Liabilities 0 (2,743,162)      
Total Liabilities   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) | Tonogold Resources, Inc.          
Assets:          
Tonogold note receivable   0 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities 1,100,293 910,558 3,939,558    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities   910,559      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) | M C U          
Assets:          
Derivative asset   0 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) | Elevation          
Assets:          
Investments in equity securities 7,449 15,260 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) | LINICO Corporation          
Liabilities:          
LINICO acquisition derivative liability   0      
LINICO acquisition derivative liability 0 (2,743,162)      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)          
Assets:          
Total assets measured at fair value 0 342,000 305,292    
Total assets measured at fair value   342,000      
Liabilities:          
GenMat derivative (4,990,000) (6,130,000)      
Total Liabilities (6,403,162) (6,130,000)      
Total Liabilities   (8,873,162)      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Tonogold Resources, Inc.          
Assets:          
Tonogold note receivable   0 0    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities 0 0 0    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | M C U          
Assets:          
Derivative asset   342,000 265,127    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Elevation          
Assets:          
Investments in equity securities 0 0 40,165    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | LINICO Corporation          
Liabilities:          
LINICO acquisition derivative liability   (2,743,162)      
LINICO acquisition derivative liability (1,413,162)        
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)          
Assets:          
Total assets measured at fair value 0 7,255,000 5,498,500    
Total assets measured at fair value   7,255,000      
Liabilities:          
GenMat derivative 0 0      
Total Liabilities 0 0      
Total Liabilities   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Tonogold Resources, Inc.          
Assets:          
Tonogold note receivable   7,255,000 5,498,500    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities 0 0 0    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Tonogold Resources, Inc. | Common Stock          
Assets:          
Investments in equity securities   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | M C U          
Assets:          
Derivative asset   0 0    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Elevation          
Assets:          
Investments in equity securities 0 0 $ 0    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | LINICO Corporation          
Liabilities:          
LINICO acquisition derivative liability   0      
LINICO acquisition derivative liability $ 0 $ 0